title: A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation.
abstract: The gut microbiota is an important contributor to the worldwide prevalence of metabolic syndrome (MS), which includes obesity and diabetes. The anti-MS effects exerted by Bifidobacterium animalis ssp. lactis GCL2505 (BlaG), a highly proliferative Bifidobacterium strain in the gut, and B. longum ssp. longum JCM1217T(BloJ) were comparatively examined. BlaG treatment reduced visceral fat accumulation and improved glucose tolerance, whereas BloJ had no effect on these parameters. Gut microbial analysis revealed that BlaG exerted stronger effects on the overall bacterial structure of the gut microbiota than BloJ, including enrichment of the genus Bifidobacterium. The levels of acetate and glucagon-like peptide-1 were increased by BlaG treatment in both the gut and plasma, but not by BloJ treatment. Correlation analysis suggested that the elevation of gut acetate levels by BlaG treatment plays a pivotal role in the BlaG-induced anti-MS effects. These findings indicated that BlaG, a highly viable and proliferative probiotic, improves metabolic disorders by modulating gut microbiota, which results in the elevation of SCFAs, especially acetate.
authors.affiliation: Institute of Health Sciences, Ezaki Glico Co., Ltd., Nishiyodogawa, Osaka 555-8502, Japan.|Graduate School of Frontier Sciences, The University of Tokyo, Chiba 277-8561, Japan.
authors.forename: Ryo
authors.initials: R
authors.lastname: Aoki
authors.affiliation: Institute of Health Sciences, Ezaki Glico Co., Ltd., Nishiyodogawa, Osaka 555-8502, Japan.
authors.forename: Kohei
authors.initials: K
authors.lastname: Kamikado
authors.affiliation: Graduate School of Frontier Sciences, The University of Tokyo, Chiba 277-8561, Japan.|Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo 160-8582, Japan.
authors.forename: Wataru
authors.initials: W
authors.lastname: Suda
authors.affiliation: Institute of Health Sciences, Ezaki Glico Co., Ltd., Nishiyodogawa, Osaka 555-8502, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takii
authors.affiliation: Institute of Health Sciences, Ezaki Glico Co., Ltd., Nishiyodogawa, Osaka 555-8502, Japan.
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Mikami
authors.affiliation: Institute of Health Sciences, Ezaki Glico Co., Ltd., Nishiyodogawa, Osaka 555-8502, Japan.
authors.forename: Natsuki
authors.initials: N
authors.lastname: Suganuma
authors.affiliation: Graduate School of Frontier Sciences, The University of Tokyo, Chiba 277-8561, Japan.|Graduate School of Advanced Science and Engineering, Waseda University, Tokyo 169-8555, Japan.
authors.forename: Masahira
authors.initials: M
authors.lastname: Hattori
authors.affiliation: Department of Infectious Diseases, Tokai University School of Medicine, Isehara, Kanagawa 259-1143, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Koga
mesh_terms: D000085:Acetates / Q000378:metabolism*; D000818:Animals; D001644:Bifidobacterium / Q000378:metabolism*; D004195:Disease Models, Animal; D000069196:Gastrointestinal Microbiome; D005947:Glucose / Q000378:metabolism; D018149:Glucose Intolerance / Q000378:metabolism / Q000628:therapy; D008297:Male; D008659:Metabolic Diseases / Q000209:etiology / Q000378:metabolism* / Q000628:therapy; D054892:Metagenome; D056186:Metagenomics / Q000379:methods; D051379:Mice; D019936:Probiotics
chemical_list: D000085:Acetates; D005947:Glucose